Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
See Latest ArticlesThe duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity
European Journal of Immunology, 08/05/09
Riquelme E et al. – Intermediate TCR/pMHC t1/2 induced strong expression of cytotoxic molecules, efficient polarization of lytic machinery and subsequent release of toxic granules by CTL that killed tumor cells. Consistently, efficient in vivo CTL–mediated tumor clearance was only observed for tumors expressing intermediate t1/2 pMHC ligands. These data suggest that there is an optimal TCR/pMHC t1/2 for efficient CTL activity.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Factors affecting neutrophil recovery after autologous bone marrow-derived stem cell transplantation in patients with acute myeloid leukemia
Transplantation Proceedings, 11/23/09
Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer–Specific Immune Responses and Their Correlation to Prognosis
Cancer Research, 11/03/09
Immune Responses in Patients with Metastatic Renal Cell Carcinoma Treated with Dendritic Cells Pulsed with Tumor Lysate
Scandinavian Journal of Immunology, 11/02/09
Sponsor
Article Search
Sponsor